Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 7/20 | 0.57 |
| ▸ | ICMT | O60725 | 8/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752610 | 0.87 | SERPINE1 (0.74) | SERPINE1ICMTMAPK1L3MBTL1 | |
| SCHEMBL5568001 | 0.87 | SERPINE1 (0.77) | SERPINE1ICMTLMNAALDH1A1 | |
| SCHEMBL5572599 | 0.79 | SERPINE1 (0.60) | SERPINE1ICMTLMNAALDH1A1 | |
| SCHEMBL5571633 | 0.78 | SERPINE1 (0.66) | SERPINE1ICMTMAPK1L3MBTL1 | |
| SCHEMBL3948740 | 0.75 | SERPINE1 (0.82) | SERPINE1ICMTMAPK1L3MBTL1 | |
| SCHEMBL3858380 | 0.75 | SERPINE1 (0.86) | SERPINE1ICMTMAPK1L3MBTL1 | |
| Aleplasinin SCHEMBL3861891 | 0.73 | SERPINE1 (1.00) | SERPINE1ICMTMAPK1L3MBTL1 | |
| Aleplasinin SCHEMBL29377702 | 0.73 | SERPINE1 (1.00) | SERPINE1ICMTMAPK1L3MBTL1 | |
| SCHEMBL4937637 | 0.72 | SERPINE1 (0.80) | SERPINE1ICMT | |
| SCHEMBL4789435 | 0.71 | SERPINE1 (0.79) | SERPINE1ICMTMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844771-A2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | Wyeth (US) | 2007-10-17 | — | — | EP | claimed |
| US-7074817-B2 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-07-11 | — | — | US | claimed |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | TFPI, SERPINE1, PLAT | SERPINE1 2/4885ICMT 2468/4885MAPK1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.